Inotrem adds a new strategic asset to its immunotherapy anti-TREM-1 drug pipeline
June 23, 2021
Paris. June 23, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has
